Hypothesis-Generating Brief: Statins longevity — full paper

Researka accepted publication: e7c852f1-873a-4cb5-98d6-2f49fad6de83 Source submission: 30b8af18-f881-419d-86bc-5f8a1f4425b1 Evidence-honesty note: 32/53 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 50/53 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Statins are among the most widely prescribed drug classes, yet their effects on human longevity, geroscience-relevant functional decline, and disease-specific survival remain contested, with the question intensifying as multimorbid older adults are increasingly considered for initiation or deprescribing (Aebi 2025; Vordenberg 2026). Functional surrogates in older adults carry prognostic weight well beyond lipid numbers — for example, gait speed near 0.8 m/s has been tied to frailty risk (Studenski 2011), and an annual decline of 0.